Doctors Warn of Drug-Resistant Superbug Spread in the U.S.

Healthcare professionals are increasingly concerned about a drug-resistant superbug making its way across the United States.

Shigellosis, which can spread easily through fecal contact, leads to severe symptoms like intense diarrhea and significant stomach cramps.

While many individuals recover within a week with rest, there are severe cases where individuals endure prolonged diarrhea that can lead to dehydration, which poses serious health risks.

Normally, these infections are addressed promptly with antibiotics. However, the CDC has raised alarms that a new drug-resistant strain, known as XDR, is compromising the efficacy of these treatments.

According to a recent report, the drug-resistant form of shigellosis was virtually nonexistent in 2011 but accounted for around 8.5 percent of cases in 2023, a figure that appears to be climbing.

Moreover, approximately one-third of those infected with this resistant strain required hospitalization, a stark contrast to the usual hospitalization rate of just one percent.

No fatalities linked to this resistant strain have been reported in the U.S. as of now.

Health officials deem this situation a “public health threat” and have called for improved monitoring to curb its progression.

Annually, around 450,000 Americans contract shigella bacteria, leading to approximately 6,000 hospitalizations and 40 deaths.

Symptoms typically linger for about a week and are notably more intense than those caused by norovirus, which affects about 19 million Americans each year with symptoms that last one to two days. Children under five appear particularly vulnerable to infection.

Historically, outbreaks of shigellosis have predominantly affected children, especially in settings like daycare centers and schools.

However, the latest findings indicate that the drug-resistant variant is often found in middle-aged men.

The report examined data from the CDC’s Pulsenet surveillance network for notifiable diseases like shigellosis. Between January 2011 and October 2023, there were 16,788 shigellosis infections, with 505 linked to the drug-resistant strain.

Infections were minimal in the U.S. until 2020, at which point there was a noticeable increase. By 2023, the resistant strain was responsible for 280 out of 3,500 reported cases—effectively eight percent.

Regionally, the Western U.S. saw the highest number of infections, accounting for 54 percent of drug-resistant cases in 2023, with the Northeast following at 38 percent.

In the latest year, the South and Midwest reported about 10 percent each of the drug-resistant infections. The majority of these cases were identified as shigella sonnei and shigella flexneri, with resistance to several antibiotics noted.

Interestingly, the demographic data shows that 86.2 percent of the infected patients were male, averaging 41 years old. A striking 76 percent reported no recent domestic travel, and 82 percent denied any international travel, even though travel usually poses a significant risk for shigella exposure via contaminated food or water.

This infection is notably contagious, with just 10 shigella bacteria needed to trigger illness, releasing toxins leading to the disease.

The emergence of this resistant strain adds to the list of drug-resistant pathogens appearing in the U.S. Annually, around 236 million antibiotic prescriptions are written, with millions more doses administered to animals to prevent infections and enhance meat production.

This extensive antibiotic use raises concerns about the development of resistant bacterial strains that can convert previously treatable conditions into dire illnesses. Right now, over 2.8 million drug-resistant bacterial infections are diagnosed each year in the U.S., resulting in about 35,000 deaths annually—approximately one every 15 minutes.

Experts caution that, without intervention, the prevalence of drug-resistant infections is likely to increase.